By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

This was the stock's second consecutive day of gains.

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce — about 50 employees — to help extend its cash into ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb ...